SML0289
Bromfenac sodium
≥98% (HPLC), COX1 and COX2 inhibitor, powder
Synonym(s):
2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H11BrNNaO3
CAS Number:
Molecular Weight:
356.15
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Bromfenac sodium, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
faintly yellow to dark yellow
solubility
H2O: ≥5 mg/mL
storage temp.
2-8°C
SMILES string
[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2
InChI
1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1
InChI key
HZFGMQJYAFHESD-UHFFFAOYSA-M
Gene Information
human ... PTGS1(5742), PTGS2(5743)
Application
Bromfenac sodium has been used:
- to study its ability to bind to melanin
- in the synthesis of bromfenac indolinone standard
- to analyze its permeability in porcine conjunctiva
Biochem/physiol Actions
Bromfenac exhibits antipyretic and prostaglandin synthetase inhibiting properties. It has therapeutic properties against the reduction of ocular pain and inflammation in postoperative cataract patients. Bromfenac acts as an effective agent against allergic conjunctivitis. It has the potential to treat acute muscle pain, osteoarthritis, and rheumatoid arthritis.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID) that inhibits both COX1 and COX2. It is used as an opthalmic analgesic.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID); COX1 and COX2 inhibitor; opthalmic analgesic.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Eiichi Uchio et al.
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 221(3), 153-158 (2007-04-19)
We evaluated the efficacy and safety of long-term management of patients with vernal keratoconjunctivitis (VKC) with bromfenac sodium eye drops in combination with corticosteroids and anti-allergic eye drops. Twenty-two patients with VKC were randomly assigned to receive two test eye
Naoko Endo et al.
Acta ophthalmologica, 88(8), 896-900 (2009-09-04)
To compare the efficacy of bromfenac sodium ophthalmic solution (BF) and a steroidal solution (ST) administered prophylactically against cystoid macular oedema and anterior-chamber inflammation after phacoemulsification and intraocular lens implantation and to assess macular thickness changes using optical coherence tomography
Steven M Silverstein et al.
Current medical research and opinion, 27(9), 1693-1703 (2011-07-15)
To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.09% dosed once daily for the treatment of ocular inflammation and pain following cataract extraction with posterior chamber intraocular lens implantation. A total of 455 subjects (455 study eyes: